PPLPHARMA211.99

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹28,134 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity0.231.12-3.99-3.99
Return on Assets0.120.58-1.81-1.81
Return on Capital Employed4.165.280.680.68
Return on Invested Capital1.522.020.731.24
Margins
EBITDA Margin14.6415.7910.3910.97
Operating Margin5.586.871.021.02
Incremental Operating Margin17.63190.75
Pretax Margin1.473.73-2.63-1.77
Net Income Margin0.221.00-3.68-3.41
Net Income to Common Margin1.00-3.68-3.41
FCF Margin3.582.498.608.60
Additional
Effective Tax Rate134.7894.67-64.25-128.55
Dvd Payout Ratio0.0015.88-5.69
Sustainable Growth Rate0.230.94-4.22-3.99
Incremental Operating Margin %17.63190.7518.51
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.